The preclinical pharmacological profile of WAY-132983, a potent M1 preferring agonist

Journal of Pharmacology and Experimental Therapeutics

Volumn 292, Issue 2, 2000, Pages 584-596

  Bartolomeo, Adam C ^a   Morris, Herman ^a   Buccafusco, Jerry J ^b,c   Kille, Nancy ^b,c   Rosenzweig Lipson, Sharon ^a   Husbands, Morris G ^a   Sabb, Annmarie L ^a   Abou Gharbia, Magid ^a   Moyer, John A ^a   Boast, Carl A ^a  

^a PFIZER INC   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (3 HEXYLTHIO 2 PYRAZINYLOXY) 1 AZABICYCLO[2.2.1]HEPTANE; ARECOLINE; METHYLSCOPOLAMINE; MUSCARINIC M1 RECEPTOR AGONIST; OXOTREMORINE; PILOCARPINE; SCOPOLAMINE; UNCLASSIFIED DRUG; XANOMELINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; COGNITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; HYPOTHERMIA; MALE; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; RAT; SALIVATION;

ANIMALS; AZIRIDINES; BEHAVIOR, ANIMAL; BRAIN; BRIDGED COMPOUNDS; CHOLINE; CHOLINE O-ACETYLTRANSFERASE; COGNITION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; FRONTAL LOBE; HIPPOCAMPUS; HYPOTHERMIA; MACACA MULATTA; MALE; MICE; MUSCARINIC AGONISTS; NEUROMUSCULAR BLOCKING AGENTS; PYRAZINES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; SALIVATION; SCOPOLAMINE; THIADIAZOLES; TIME FACTORS; VISUAL CORTEX;

EID: 0033979762     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Asthana S, Greig NH, Holloway HW, Raffaele KC, Berardi MB, Rapoport SI and Soncrant TT (1996) Clinical pharmacokinetics of arecoline in subjects with Alzheimer's disease. Clin Pharmacol Ther 60:276-282.
2. Avery EE, Baker LD and Asthana S (1997) Potential role of muscarinic agonists in Alzheimers disease. Drugs Aging 11:450-459.
3. Bartolomeo AC, Morris H and Boast CA (1997) Arecoline via miniosmotic pump improves AF64A-impaired radial maze performance in rats: A possible model of Alzheimer's disease. Neurobiol Learn Mem 68:333-342.
4. Bartus RT, Dean RL III, Beer B and Lippa AS (1982) The cholinergic hypothesis of memory dysfunction. Science (Wash DC) 217:408-417.
5. Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, Shannon HE, Tollefson GD, Rasmussen K, Bymaster FP, Hurley DJ, Potter WZ and Paul SM (1997) Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer's disease. Arch Neurol 54:465-473.
6. Bonner TI (1989) The molecular basis of muscarinic receptor diversity. Trends Neurosci 12:148-151.
7. Buccafusco JJ, Jackson WJ, Terry AV Jr, Marsh KC, Decker MW and Arneric SP (1995) Improvement in performance of a delayed matching-to-sample task by monkeys following ABT-418: A novel cholinergic channel activator for memory enhancement. Psychopharmacology 120:256-266.
8. Clement JG (1994) Chromodacryorrhea in rats: Absence following soman poisoning. Toxicol Appl Pharmacol 124:52-58.
9. Dai Y, Ambudkar IS, Horn VJ, Yeh C, Kousvelari EE, Wall SJ, Yasuda RP, Wolfe BB and Baum BJ (1991) Evidence that M3 muscarinic receptors in rat parotid gland couple to two second messenger systems. Am J Physiol 261:C1063-C1073.
10. DeKosky ST, Harbaugh RE, Schmitt FA, Bakay RAE, Chui HC, Knopman DS, Reeder TM, Shetter AG, Senter HJ, Markesbery WR and the Intraventricular Bethanecol Study Group (1992) Cortical biopsy in Alzheimer's disease: Diagnostic accuracy and neurochemical, neuropathological and cognitive correlations. Ann Neurol 32:625-632.
11. Eckols K, Bymaster FP, Mitch CH, Shannon HE, Ward JS and DeLapp NW (1995) The muscarinic M1 agonist xanomeline increases soluble amyloid precursor protein release from Chinese hamster ovary-M1 cells. Life Sci 57:1183-1190.
12. Fisher A, Heldman E, Gurwitz D, Haring R, Karton Y, Meshulam H, Pittel Z, Marciano D, Brandeis R, Sadot E, Barg Y, Pinkas-Kramarski R, Vogel Z, Ginzburg I, Treves TA, Verchovsky R, Klimowsky S and Korczyn AD (1996) M1 agonists for the treatment of Alzheimer's disease: Novel properties and clinical update. Ann NYAcad Sci 777:189-196.
13. Gracon SI (1996) Evaluation of tacrine hydrochloride (Cognex) in two parallel-group studies. Acta Neurol Scand Suppl 165:114-122.
14. Jackson WJ, Buccafusco JJ, Terry AV, Turk DJ and Rush DK (1995) Velnacrine maleate improves delayed matehing performance by aged monkeys. Psychophar7 macology 119:391-398.
15. Ladner CJ, Celesia GG, Magnuson DJ and Lee JM (1995) Regional alterations in M1 muscarinic receptor-G protein coupling in Alzheimer's disease. J Neuropathol Exp Neurol 54:783-789.
16. Loudon JM, Bromidge SM, Brown F, Clark MS, Hatcher JP, Hawkins J, Riley GJ, Noy G and Orlek BS (1997) SB 202026: A novel muscarinic partial agonist with functional selectivity for M1 receptors. J Pharmacol Exp Ther 283:1059-1068.
17. Pearce BD and Potter LT (1991) Coupling of M1 muscarinic receptors to G protein in Alzheimer disease. Alz Dis Assoc Disord 5:163-172.
18. Pilcher JJ, Sessions GR and McBride SA (1997) Scopolamine impairs spatial working memory in the radial maze: An analysis by error type and arm choice. Pharmacol Biochem Behau 58:449-459.
19. Prendergast MA, Jackson WJ, Terry AV Jr, Kille NJ, Arneric SP, Decker MW and Buccarusco JJ (1998) Age-related differences in distractibility and response to methylphenidate in monkeys. Cerebral Cortex 8:164-172.
20. Rho JP and Lipson LG (1997) Focus on donepezil: A reversible acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Hasp Form 32:677-684.
21. Sabb AL, Husbands GM, Tokolics J, Stein RP, Tasse RP, Boast CA, Moyer JA and Abou-Gharbia M (1999) Discovery of a highly potent, functionally-selective muscarinic M1 agonist, WAY-132983, using rational drug design and receptor modelling. Bioorg Med Chem Lett 9:1895-1900.
22. Sadot E, Gurwitz D, Barg J, Behar L, Ginzburg I and Fisher A (1996) Activation of M1 muscarinic acetylcholine receptor regulates tau phosphorylation in transfected PC12 cells. J Neurochem 66:877-880.
23. Sanchez C and Løve Lembøl H (1994) The involvement of muscarinic receptor subtypes in the mediation of hypothermia, tremor and salivation in male mice. Pharmacol Toxicol 74:35-39.
24. Schiavone A and Brambilla A (1991) Muscarinic M3 receptors mediate secretion from sweat glands in the rat. Pharmacol Res 23:233-239.
25. Sen AP and Bhattacharya SK (1991) Thermic response of selective muscarinic agonists and antagonists in rat. Indian J Exp Biol 29:131-135.
26. Shannon HE, Bymaster FP, Calligaro DO, Greenwood B, Mitch CH, Sawyer BD, Ward JS, Wong DT, Olesen PH, Sheardown MJ, Swedeberg MDB, Suzdak PD and Sauerberg P (1994) Xanomeline: A novel muscarinic receptor agonist with functional selectivity for M1 receptors. J Pharmacol Exp Ther 269:271-281.
27. Slack BE, Nitsch RM, Livneh E, Kunz GM Jr, Breu J, Eldar H and Wurtman RJ (1993) Regulation by phorbol esters of amyloid precursor protein release from Swiss 3T3 fibroblasts overexpressing protein kinase C alpha. J Biol Chem 268: 21097-21101.
28. Soncrant TT, Raffaele KC, Asthana S, Berardi A, Morris P and Haxby JV (1993) Memory improvement without toxicity during chronic, low dose intravenous arecoline in Alzheimer's disease. Psychopharmacology 112:421-427.
29. Stewart DJ, Leventer SM, Hanin I and Vanderwolf CH (1987) Hippocampal electrical activity in relation to behavior following ethylcholine aziridinium ion (AF64A) treatment. Pharmacol Biochem Behav 26:357-364.
30. Symons JP, Smith M, Marriott JG and Davis RE (1986) Effects of muscarinic cholinergic agents on spontaneous swimming in rats. Soc Neurosci Abstr 12:897.
31. Tasse R, Husbands M, Kowal D, Fairman D, Malhorta D, Chanda P, Abou-Gharbia M and Moyer JA (1997) WAY-132983 and its in-vitro profile of muscarinic activities in recombinant CHO cell lines. Soc Neurosci Abstr 23:1367.
32. Terry AV Jr, Buccafusoo JJ and Jackson WJ (1993a) Scopolamine reversal of nicotine enhanced delayed matching-to-sample performance in monkeys. Pharmacol Biochem Behav 45:925-929.
33. Terry AV Jr, Jackson WJ and Buccafusco JJ (1993b) Effects of concomitant cholinergic and adrenergic stimulation on learning and memory performance by young and aged monkeys. Cerebral Cortex 3:304-312.
34. Thorne B and Potter PE (1995) Lesion with the neurotoxin AF64A alters hippocampal cholinergic receptor function. Brain Res Bull 38:121-127.
35. Walland A, Burkard S, Hammer R and Troger W (1997) In vivo consequences of M1-receptor activation by talsaclidine. Life Sci 60:977-984.
36. Walsh TJ, Tilson HA, DeHaven DL, Mailman RB, Fisher A and Hanin I (1984) AF64A, a cholinergic neurotoxin, selectively depletes acetylcholine in hippocampus and cortex, and produces long-term passive avoidance and radial-arm maze deficits in the rat. Brain Res 321:91-102.
37. Witkin JM, Alvarado-Garcia R, Lee MA and Witkin KM (1987) Nonmuscarinic neurotoxicity of oxotremorine. J Pharmacol Exp Ther 241:34-41.
38. Xiong ZQ, Han YF and Tang XC (1995) Huperazine A ameliorates the spatial working memory impairments induced by AF64A Neuroreport 6:2221-2224.